 Neoplasm Grading
"Neoplasm Grading" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Methods which attempt to express in replicable terms the level of CELL DIFFERENTIATION in neoplasms as increasing ANAPLASIA correlates with the aggressiveness of the neoplasm.
| Descriptor ID |
D060787
|
| MeSH Number(s) |
E01.789.612
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Neoplasm Grading".
Below are MeSH descriptors whose meaning is more specific than "Neoplasm Grading".
This graph shows the total number of publications written about "Neoplasm Grading" by people in this website by year, and whether "Neoplasm Grading" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2012 | 0 | 1 | 1 | | 2013 | 1 | 4 | 5 | | 2014 | 0 | 3 | 3 | | 2016 | 0 | 3 | 3 | | 2017 | 0 | 3 | 3 | | 2018 | 0 | 1 | 1 | | 2020 | 1 | 1 | 2 | | 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Neoplasm Grading" by people in Profiles.
-
Nordstr?m T, Discacciati A, Bergman M, Clements M, Aly M, Annerstedt M, Glaessgen A, Carlsson S, J?derling F, Eklund M, Gr?nberg H. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial. Lancet Oncol. 2021 09; 22(9):1240-1249.
-
Egevad L, Swanberg D, Delahunt B, Str?m P, Kartasalo K, Olsson H, Berney DM, Bostwick DG, Evans AJ, Humphrey PA, Iczkowski KA, Kench JG, Kristiansen G, Leite KRM, McKenney JK, Oxley J, Pan CC, Samaratunga H, Srigley JR, Takahashi H, Tsuzuki T, van der Kwast T, Varma M, Zhou M, Clements M, Eklund M. Identification of areas of grading difficulties in prostate cancer and comparison with artificial intelligence assisted grading. Virchows Arch. 2020 Dec; 477(6):777-786.
-
Plym A, Clements M, Voss M, Holmberg L, Stattin P, Lambe M. Duration of sick leave after active surveillance, surgery or radiotherapy for localised prostate cancer: a nationwide cohort study. BMJ Open. 2020 03 09; 10(3):e032914.
-
Palsdottir T, Nordstr?m T, Aly M, J?derling F, Clements M, Gr?nberg H, Eklund M. A Unified Prostate Cancer Risk Prediction Model Combining the Stockholm3 Test and Magnetic Resonance Imaging. Eur Urol Oncol. 2019 09; 2(5):490-496.
-
Lawrence YR, Samueli B, Levitin R, Pail O, Spieler B, Pfeffer R, Goldstein J, Den RB, Symon Z. Do Prostate Cancer Patients With Markedly Elevated PSA Benefit From Radiation Therapy?: A Population-based Study. Am J Clin Oncol. 2017 Dec; 40(6):605-611.
-
Goode EL, Block MS, Kalli KR, Vierkant RA, Chen W, Fogarty ZC, Gentry-Maharaj A, Toloczko A, Hein A, Bouligny AL, Jensen A, Osorio A, Hartkopf A, Ryan A, Chudecka-Glaz A, Magliocco AM, Hartmann A, Jung AY, Gao B, Hernandez BY, Fridley BL, McCauley BM, Kennedy CJ, Wang C, Karpinskyj C, de Sousa CB, Tiezzi DG, Wachter DL, Herpel E, Taran FA, Modugno F, Nelson G, Lubinski J, Menkiszak J, Alsop J, Lester J, Garc?a-Donas J, Nation J, Palacios J, Rothstein JH, Kelley JL, de Andrade JM, Robles-D?az L, Intermaggio MP, Widschwendter M, Beckmann MW, Ruebner M, Jimenez-Linan M, Singh N, Oszurek O, Harnett PR, Rambau PF, Sinn P, Wagner P, Ghatage P, Sharma R, Edwards RP, Ness RB, Orsulic S, Brucker SY, Johnatty SE, Longacre TA, Ursula E, McGuire V, Sieh W, Natanzon Y, Li Z, Whittemore AS, Anna A, Staebler A, Karlan BY, Gilks B, Bowtell DD, H?gdall E, Candido dos Reis FJ, Steed H, Campbell IG, Gronwald J, Ben?tez J, Koziak JM, Chang-Claude J, Moysich KB, Kelemen LE, Cook LS, Goodman MT, Garc?a MJ, Fasching PA, Kommoss S, Deen S, Kjaer SK, Menon U, Brenton JD, Pharoah PDP, Chenevix-Trench G, Huntsman DG, Winham SJ, K?bel M, Ramus SJ. Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. JAMA Oncol. 2017 12 01; 3(12):e173290.
-
Earp MA, Raghavan R, Li Q, Dai J, Winham SJ, Cunningham JM, Natanzon Y, Kalli KR, Hou X, Weroha SJ, Haluska P, Lawrenson K, Gayther SA, Wang C, Goode EL, Fridley BL. Characterization of fusion genes in common and rare epithelial ovarian cancer histologic subtypes. Oncotarget. 2017 Jul 18; 8(29):46891-46899.
-
Sasaki K, Kurahara H, Young ED, Natsugoe S, Ijichi A, Iwakuma T, Welch DR. Genome-wide in vivo RNAi screen identifies ITIH5 as a metastasis suppressor in pancreatic cancer. Clin Exp Metastasis. 2017 04; 34(3-4):229-239.
-
Way GP, Rudd J, Wang C, Hamidi H, Fridley BL, Konecny GE, Goode EL, Greene CS, Doherty JA. Comprehensive Cross-Population Analysis of High-Grade Serous Ovarian Cancer Supports No More Than Three Subtypes. G3 (Bethesda). 2016 12 07; 6(12):4097-4103.
-
Yao M, Yu E, Staggs V, Fan F, Cheng N. Elevated expression of chemokine C-C ligand 2 in stroma is associated with recurrent basal-like breast cancers. Mod Pathol. 2016 08; 29(8):810-23.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|